Welcome back to another installment of Covestor Radio, a show about money milestones and investing for your future.
In our latest show, Kimberly Clouse, Private Client Advocate and Chair of Covestor’s Advisory Board, talks about what determines an investor’s type and why it is important.
Her full appearance on Covestor Radio is embedded below:
A number of Covestor models use leveraged ETFs as part of their investment strategy. SymmetricInfo has a two-part post illustrating the mechanics […]
Apple to $1000? Cody Willard at MarketWatch thinks so. But it’s the two fundamental arguments he makes that offer more value than any price target.
In June, the American Society of Clinical Oncology (ASCO) hosted its 60th Annual Meeting, drawing over 40,000 attendees from around the globe. This year’s event largely focused on validating revolutionary treatment categories like Chimeric antigen receptor (CAR) T-cell therapies and antibody drug conjugates (ADCs). Given proven clinical benefits across a wider array of cancer types, we expect these novel treatment categories to become increasingly important in the fight against cancer and the growth profiles of select companies in the healthcare space.
Investors closed the month of February with their highest net long exposure in 14 months, according to Lipper data.
